View Document Preview and Link Document Date: 2013-02-28 08:53:55 Open Document File Size: 38,07 KB Share Result on Facebook
City Mont / Lille / Brussels / / Company Sopartec S.A. / Mitsui / Chief Scientific Officer / Media & Analysts Contact Andrew Lloyd & Associates / Paediatric Clinical Investigation Center / Promethera Biosciences SA / / Continent Europe / / Country Italy / Belgium / France / United States / United Kingdom / / Currency EUR / / / Event Business Partnership / Funding / FDA Phase / / Facility University Children’s Hospital Jeanne / / IndustryTerm therapies for the treatment of liver disease / biotechnology / pharmaceutical industry / cell therapy product / chemical compounds / non-therapeutic product / pharmaceutical / biotechnology tool / treatment of liver-based metabolic diseases / chemical entities / clinical site / spin-off / technology transfer / / MedicalCondition Inherited Metabolic Diseases / rare inborn metabolic diseases / Urea Cycle Disorders / daily disease / fulminant hepatitis / liver disease / Ornithine Transcarbamylase Deficiency / liver diseases / Crigler-Najjar Syndrome / Urea Cycle Disorder / liver fibrosis / Crigler Najjar syndrome / diseases / liver-based metabolic diseases / pediatric liver disease / Phase I/II clinical study involving Crigler-Najjar syndrome / / MedicalTreatment liver stem cell therapy / innovative therapies / cell therapy / / Organization Food and Drug Administration / University Children’s Hospital / BI Venture Fund / UCL’s Cell Therapy Research Lab / European Medicines Agency / MHRA / UCL / Ethics Committee / / Person Béatrice De Vos / Neil Hunter / Najimi / Jeanne de Flandre / Frederic Gottrand / Dries Dobbelaere / Etienne Sokal / Juliette dos Santos / Eric Halioua / Frédérique Ramon / / / Position co-founder / co-founder and Chief Executive Officer / Chief Medical Officer / CEO / Professor / Director / Chief Scientific Officer / / Product Promethera / / Technology cell therapy / biotechnology / stem cells / / URL www.promethera.com / / SocialTag 
Promethera Biosciences opens the French part of its clinical trial in cell therapy Promethera successfully administers Promethera® HepaStem in an adolescent suffering from an Urea Cycle Disorder at Hôpital Jeanne de Fl